Climate and Energy-Water-Land System Interactions Technical Report to the U.S. Department of Energy in Support of the National Climate Assessment

This report provides a framework to characterize and understand the important elements of climate and energy-water-land (EWL) system interactions. It identifies many of the important issues, discusses our understanding of those issues, and presents a long-term research program research needs to address the priority scientific challenges and gaps in our understanding. Much of the discussion is organized around two discrete case studies with the broad themes of (1) extreme events and (2) regional intercomparisons. These case studies help demonstrate unique ways in which energy-water-land interactions can occur and be influenced by climate

A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy : the TURRIFIC randomised trial

BackgroundSevere early onset (less than 34weeks gestation) intrahepatic cholestasis of pregnancy (ICP) affects 0.1% of pregnant women in Australia and is associated with a 3-fold increased risk of stillbirth, fetal hypoxia and compromise, spontaneous preterm birth, as well as increased frequencies of pre-eclampsia and gestational diabetes. ICP is often familial and overlaps with other cholestatic disorders.Treatment options for ICP are not well established, although there are limited data to support the use of ursodeoxycholic acid (UDCA) to relieve pruritus, the main symptom. Rifampicin, a widely used antibiotic including in pregnant women, is effective in reducing pruritus in non-pregnancy cholestasis and has been used as a supplement to UDCA in severe ICP. Many women with ICP are electively delivered preterm, although there are no randomised data to support this approach.MethodsWe have initiated an international multicentre randomised clinical trial to compare the clinical efficacy of rifampicin tablets (300mg bd) with that of UDCA tablets (up to 2000mg daily) in reducing pruritus in women with ICP, using visual pruritus scores as a measuring tool.DiscussionOur study will be the first to examine the outcomes of treatment specifically in the severe early onset form of ICP, comparing "standard" UDCA therapy with rifampicin, and so be able to provide for the first-time high-quality evidence for use of rifampicin in severe ICP. It will also allow an assessment of feasibility of a future trial to test whether elective early delivery in severe ICP is beneficial.Trial identifiersAustralian New Zealand Clinical Trials Registration Number (ANZCTR): 12618000332224p (29/08/2018). HREC No: HREC/18/WCHN/36.EudraCT number: 2018-004011-44.IRAS: 272398.NHMRC registration: APP1152418 and APP117853.Peer reviewe

A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial

BackgroundSevere early onset (less than 34weeks gestation) intrahepatic cholestasis of pregnancy (ICP) affects 0.1% of pregnant women in Australia and is associated with a 3-fold increased risk of stillbirth, fetal hypoxia and compromise, spontaneous preterm birth, as well as increased frequencies of pre-eclampsia and gestational diabetes. ICP is often familial and overlaps with other cholestatic disorders.Treatment options for ICP are not well established, although there are limited data to support the use of ursodeoxycholic acid (UDCA) to relieve pruritus, the main symptom. Rifampicin, a widely used antibiotic including in pregnant women, is effective in reducing pruritus in non-pregnancy cholestasis and has been used as a supplement to UDCA in severe ICP. Many women with ICP are electively delivered preterm, although there are no randomised data to support this approach.MethodsWe have initiated an international multicentre randomised clinical trial to compare the clinical efficacy of rifampicin tablets (300mg bd) with that of UDCA tablets (up to 2000mg daily) in reducing pruritus in women with ICP, using visual pruritus scores as a measuring tool.DiscussionOur study will be the first to examine the outcomes of treatment specifically in the severe early onset form of ICP, comparing "standard" UDCA therapy with rifampicin, and so be able to provide for the first-time high-quality evidence for use of rifampicin in severe ICP. It will also allow an assessment of feasibility of a future trial to test whether elective early delivery in severe ICP is beneficial.Trial identifiersAustralian New Zealand Clinical Trials Registration Number (ANZCTR): 12618000332224p (29/08/2018). HREC No: HREC/18/WCHN/36.EudraCT number: 2018-004011-44.IRAS: 272398.NHMRC registration: APP1152418 and APP117853

Walking city

The United Nations estimates that by 2030, more than two-thirds of the total world population will live in urban areas. Most of this increase will take place not in Europe or in the United States but in the megacities and newly emerging urban regions of what used to be called the developing world.Urban studies is an expansive and growing field, covering many disciplines and professional fields, each with its own schedule of conferences, journals, and publication series. These two volumes address the specific theories, key studies, and important figures that have influenced not just the individual discipline but also the field of urban studies more generally. The Encyclopedia of Urban Studies is intended to present an overview of current work in the field and to serve as a guide for further reading in the field. The Encyclopedia of Urban Studies serves as an introduction to topics of significance in urban studies for an audience that includes undergraduate students, beginning graduate students of urban studies and the related urban disciplines, a broader public that has an interest in the new urban world, and even established teachers and scholars who are exploring new areas of study

Analytical leapfrogging?: a conference presentation about ‘caring on the move’

This paper discusses the idea of ‘analytical leapfrogging’ by considering how and why we can sometimes be tempted to jump over or ignore a more formal analytical phase in our research. It does this by discussing a vignette presented in a conference session relating to preliminary research on everyday mobilities, care, and children with non-visible disabilities. The paper offers some critical reflections on the implications of refracting early project ideas through our own lived experiences and the significance of our analytical histories in shaping the work that we do